Pentadecapeptide BPC (Oral)

Overview

Oral BPC-157 is a stabilized oral formulation of the pentadecapeptide Body Protection Compound-157, designed to survive gastric degradation and deliver systemic healing effects via oral administration. Various salt forms (arginate, acetate) aim to improve oral bioavailability.

Mechanism of Action

Oral BPC-157 shares the same mechanism as injectable BPC-157, upregulating VEGF, EGF, and the FAK-paxillin pathway. The oral route provides direct exposure to the gastrointestinal mucosa, where it promotes gut healing, and systemic absorption delivers tissue-repair signals. Arginine salt forms may enhance stability in acidic conditions.

Research Summary

Preclinical studies confirm oral BPC-157 efficacy in models of inflammatory bowel disease, gastric ulcers, and NSAID-induced GI damage. Systemic effects (tendon, muscle, nerve healing) have been demonstrated after oral dosing in animal models, though bioavailability is lower than injectable. No human clinical trials have been published.

Dosing Information

Reported Side Effects

• Mild nausea
• Gastrointestinal discomfort
• Headache
• Dizziness

Research References

• Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract (2011)
• BPC 157 and standard angiogenic growth factors: gastrointestinal tract healing, hepatoprotection, and wound healing (2019)
• Pentadecapeptide BPC 157 — from the gastric mucosal protection to wound healing (2014)